Skip To Main Content

Transplantační medicína

Nejnovější trendy

Prozkoumejte nejčtenější články a videa na Campus Sanofi

Seřadit
Autoimmunity in Type 1 Diabetes: A Pathophysiology Snapshot

Autoimmunity in Type 1 Diabetes: A Pathophysiology Snapshot

T1D is an autoimmune disease whereby autoreactive T-cells drive progressive beta-cell damage and destruction, ultimately leading to insulin deficiency, dysglycemia, and hyperglycemia. 

 

The Silent Stages of Type 1 Diabetes: An Overview

The Silent Stages of Type 1 Diabetes: An Overview

Staging of autoimmune T1D allows us to track the progressive nature of the disease, from autoimmunity through to insulin dependence. 

Monitoring of Presymptomatic Type 1 Diabetes

Monitoring of Presymptomatic Type 1 Diabetes

Monitoring people with early-stage autoimmune T1D may reduce the risk of serious complications, such as DKA.

Early Identification of Type 1 Diabetes: Who Might Benefit from Screening for Autoantibodies?

Early Identification of Type 1 Diabetes: Who Might Benefit from Screening for Autoantibodies?

Why and Who: an overview of the key considerations and decisions that inform screening people for islet autoantibodies.

Multipel sclerose og vaccination

Multipel sclerose og vaccination

Exploring the Impact of Diagnosis

Exploring the Impact of Diagnosis

The burden associated with a diagnosis of autoimmune T1D can be wide-ranging. This video describes the impact of diagnosis on an individual and their family.

MS - Sclerose og graviditet

MS - Sclerose og graviditet

Enhancing Antiplatelet Therapy for Older Patients: Balancing Risks and Benefits

Enhancing Antiplatelet Therapy for Older Patients: Balancing Risks and Benefits

Enhancing Antiplatelet Therapy for Older Patients: Balancing Risks and Benefits

Enhancing Antiplatelet Therapy for Older Patients: Balancing Risks and Benefits

cStage III 위선암 또는 위식도접합부선암에서 docetaxel, oxaliplatin, S-1 치료의 2상 임상 연구

cStage III 위선암 또는 위식도접합부선암에서 docetaxel, oxaliplatin, S-1 치료의 2상 임상 연구

Phase 2 trial of neoadjuvant docetaxel, oxaliplatin, and S-1 for clinical stage III gastric or esophagogastric junction adenocarcinoma
Kurokawa Y, et al. Ann Gastroenterol Surg. 2022 Oct 18;7(2):247-254.

Wpływ przynależności etnicznej na strategie leczenia przeciwpłytkowego

Wpływ przynależności etnicznej na strategie leczenia przeciwpłytkowego

Związek między czasem ekspozycji na leki hipolipemizujące a względną redukcją ryzyka zdarzeń s-n

Związek między czasem ekspozycji na leki hipolipemizujące a względną redukcją ryzyka zdarzeń s-n